Yellow Dye 6 vs Recombinant Bovine Growth Hormone: which is worse?

What is Yellow Dye 6?

Yellow Dye 6 (Sunset Yellow FCF) is a synthetic orange-yellow azo dye derived from petroleum. It produces a bright orange-yellow color and is structurally similar to Yellow 5 but produces a more orange shade. Its chemical formula is C16H10N2Na2O7S2.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Yellow Dye 6: Yellow Dye 6 was included in the 2007 Lancet study (McCann et al.), which found that a mixture of six dyes including Yellow 6 and sodium benzoate significantly increased hyperactivity in children. EFSA confirmed the effect warranted mandatory warning labels in the EU. EFSA's 2009 re-evaluation examined animal carcinogenicity data and found some studies showing adrenal tumors in male mice at high doses. EFSA set an ADI of 2.5 mg/kg body weight — lower than Yellow 5's ADI of 7.5 mg/kg, reflecting greater concern. The review noted limitations in the available data. Impurity concerns: commercial batches of Yellow 6 have been found to contain aromatic amine impurities including benzidine and 4-aminobiphenyl — both IARC Group 1 human carcinogens. A 1992 CSPI analysis documented these impurities, citing them as reason for concern. A 2007 study in Toxicological Sciences found Yellow 6 altered zinc and iron biomarker levels in rat blood at high doses, raising mineral metabolism concerns. Human relevance at typical exposure is unclear. Hypersensitivity reactions including urticaria, rhinitis, and contact dermatitis are documented. Cross-reactivity with aspirin is reported similarly to Yellow 5. In April 2025, the FDA announced plans to phase out Yellow 6 with other petroleum-based dyes.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.